Private company

Inhibrx, Inc.

In its 2024 annual report the company says: “We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms. We leverage our innovative protein engineering technologies and deep understanding of target biology to create therapeutic candidates with attributes and mechanisms superior to current approaches and applicable to a range of challenging, validated targets with high potential.”4 It is headquartered in La Jolla, United States.2

Last updated Oct 20, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersLa Jolla, United States2
  • Incorporated inCA3
  • Business address11025 N. Torrey Pines Road, Suite 200, La Jolla, Ca 920373
  • Filer categoryLarge accelerated filer3
  • Legal formCorporation2
  • LEI549300VBKG2LTV1TLY222
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 65815222

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms. We leverage our innovative protein engineering technologies and deep understanding of target biology to create therapeutic candidates with attributes and mechanisms superior to current approaches and applicable to a range of challenging, validated targets with high potential.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-12178.9%Operating margin5
-13408.9%Net margin5
-17.9%Revenue growth, 20235
-554.8%Return on equity5
-$197.9MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development100¢$191.6M
  • Income tax0¢$3.0K

Out of $1.8M in revenue.5 The company lost money this year.

Financial statements

Revenue6785$1.8M in 2023−86% since 2019
0$5.0M$10.0M$15.0M2019: $13.2M$13.2M20192020: $12.9M$12.9M2020−2%2021: $7.2M$7.2M2021−44%2022: $2.2M$2.2M2022−70%2023: $1.8M$1.8M2023−18%
Operating income6785-$219.2M in 2023+401% since 2019
-$300.0M-$200.0M-$100.0M02019: -$43.7M-$43.7M20192020: -$67.4M-$67.4M2020+54%2021: -$76.6M-$76.6M2021+14%2022: -$129.1M-$129.1M2022+69%2023: -$219.2M-$219.2M2023+70%
Net income6785-$241.4M in 2023+370% since 2019
-$300.0M-$200.0M-$100.0M02019: -$51.4M-$51.4M20192020: -$76.1M-$76.1M2020+48%2021: -$81.8M-$81.8M2021+7%2022: -$145.2M-$145.2M2022+78%2023: -$241.4M-$241.4M2023+66%
Fiscal year201820192020202120222023
Revenue$13.2M6$12.9M7$7.2M8$2.2M5$1.8M5
Research and development$47.9M6$73.5M7$71.4M8$110.2M5$191.6M5
Operating expenses$83.8M8$131.3M5$221.0M5
Operating income-$43.7M6-$67.4M7-$76.6M8-$129.1M5-$219.2M5
Income before tax-$81.8M8-$145.2M8-$239.7M5
Income tax$898.0K6$3.0K7$2.0K8$3.0K5$3.0K5
Net income-$51.4M6-$76.1M7-$81.8M8-$145.2M5-$241.4M5
Earnings per share-$3.017-$2.158-$3.625-$5.125
Earnings per share (diluted)-$3.017-$2.158-$3.625-$5.125
Shares (weighted, basic)38.0M shares840.1M shares547.1M shares5
Shares (weighted, diluted)38.0M shares840.1M shares547.1M shares5

Compare Inhibrx, Inc. with another company

Corporate structure

Inhibrx, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Inhibrx, Inc.

  • PERCEPTIVE ADVISORS LLC Filed SC 13G/A on Inhibrx, Inc., latest Nov 14, 2024 (4 filings since Jul 19, 2022)
  • VIKING GLOBAL INVESTORS LP Filed SC 13G/A on Inhibrx, Inc., latest Jun 3, 2024 (4 filings since Feb 14, 2022)
  • Brendan P. Eckelman Filed SC 13G/A on Inhibrx, Inc., latest Feb 14, 2024
  • Jon Faiz Kayyem Filed SC 13G/A on Inhibrx, Inc., latest Feb 14, 2024
  • Mark Lappe Filed SC 13G/A on Inhibrx, Inc., latest Feb 14, 2024
  • RA CAPITAL MANAGEMENT, L.P. Filed SC 13G/A on Inhibrx, Inc., latest Feb 14, 2024 (3 filings since Oct 17, 2022)
  • State Street Corporation Filed SC 13G/A on Inhibrx, Inc., latest Jan 23, 2024 (2 filings since Feb 8, 2023)
  • LAV Summit Ltd Filed SC 13G/A on Inhibrx, Inc., latest Feb 9, 2022
  • Inhibrx, Inc. La Jolla, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Inhibrx, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$13.1M5 Dec 31, 2023$8.0M5 Dec 31, 2022+63.0%
Accumulated depreciation$6.7M5 Dec 31, 2023$5.5M5 Dec 31, 2022+20.7%
Property and equipment, net$6.4M5 Dec 31, 2023$2.5M5 Dec 31, 2022+156.7%
Operating-lease assets (leased space)$3.0M5 Dec 31, 2023$4.7M5 Dec 31, 2022−37.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$277.9M5 Dec 31, 2023$273.9M5 Dec 31, 2022+1.5%

Leadership

Who has led Inhibrx, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Mark Lappe2020–2024

Chief financial officer

  1. Kelly Deck2020–2024
2025
  • Chief executive officerMark Lappe Aug 18, 2020 to May 30, 202412
  • Chief financial officerKelly Deck Aug 18, 2020 to May 30, 202413
Board members and other officers (8)

Timeline

  1. May 30, 20248-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer20
  2. May 24, 20248-K Shareholder vote; Regulation FD disclosure; Other events21
  3. May 17, 20248-K Other events22
  4. May 9, 20248-K Results of operations23
  5. May 8, 20248-K Other events24
  6. Mar 12, 20248-K Other events25
  7. Feb 28, 20248-K Results of operations26
  8. Jan 23, 20248-K Entered a material agreement; Regulation FD disclosure27
  9. Nov 9, 20238-K Results of operations28
  10. Nov 2, 20238-K Other events29
  11. Sep 19, 20238-K Other events30
  12. Aug 29, 20238-K Entered a material agreement; Unregistered sale of shares; Other events31
  13. Aug 18, 2020New chief executive Mark Lappe becomes CEO12
  14. Nov 17, 2017Founded Inhibrx, Inc. is founded2

Calendar

When it reported results

  1. May 9, 2024Reported quarterly or annual results23
  2. Feb 28, 2024Reported quarterly or annual results26
  3. Nov 9, 2023Reported quarterly or annual results28
  4. Aug 7, 2023Reported quarterly or annual results32
  5. May 8, 2023Reported quarterly or annual results33
  6. Mar 6, 2023Reported quarterly or annual results34
  7. Nov 7, 2022Reported quarterly or annual results35
  8. Aug 8, 2022Reported quarterly or annual results36

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

172 filings to the SEC since October 2021: 3 annual reports, 8 quarterly reports, 43 major events, 55 insider forms, 24 large holders, 1 private raises, 38 other. The latest 20:

  1. Nov 14, 2024SC 13G/A EDGAR
  2. Jun 10, 202415-12G EDGAR
  3. Jun 3, 2024SC 13G/A EDGAR
  4. Jun 3, 20244 EDGAR
  5. May 30, 2024S-8 POS EDGAR
  6. May 30, 2024S-8 POS EDGAR
  7. May 30, 2024S-8 POS EDGAR
  8. May 30, 2024S-8 POS EDGAR
  9. May 30, 2024POSASR EDGAR
  10. May 30, 20248-K EDGAR
  11. May 30, 20244 OWNERSHIP DOCUMENT EDGAR
  12. May 30, 20244 OWNERSHIP DOCUMENT EDGAR
  13. May 30, 20244 OWNERSHIP DOCUMENT EDGAR
  14. May 30, 20244 OWNERSHIP DOCUMENT EDGAR
  15. May 30, 20244 OWNERSHIP DOCUMENT EDGAR
  16. May 30, 20244 OWNERSHIP DOCUMENT EDGAR
  17. May 30, 20244 OWNERSHIP DOCUMENT EDGAR
  18. May 28, 2024144 EDGAR
  19. May 24, 20244 EDGAR
  20. May 24, 20248-K EDGAR

The 172 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

26 open-market trades by officers, directors and large owners since October 2021: 2 buys and 24 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 28, 2024Eckelman Brendan P.Chief Scientific OfficerSale300,000$34.30$10.3MForm 4
Aug 28, 2023Ott David C.10% ownerBuy511,627$19.35$9.9MForm 4
Mar 1, 2023Eckelman Living Trust Dated February 5, 201410% ownerSale40,000$24.21$968.2KForm 4
Feb 28, 2023Lappe MarkChief Executive OfficerSale60$25.02$1.5KForm 4
Feb 2, 2023Eckelman Brendan P.Chief Scientific OfficerSale11,250$25.45$286.3KForm 4
Feb 1, 2023Eckelman Brendan P.Chief Scientific OfficerSale28,750$24.72$710.8KForm 4
Jan 24, 2023Lappe Family TrustSale4,335$25.72$111.5KForm 4
Jan 23, 2023Lappe Family TrustSale21,665$25.36$549.4KForm 4
Jan 23, 2023Kayyem Jon FaizDirectorSale9,500$25.26$240.0KForm 4
Jan 4, 2023Eckelman Living Trust Dated February 5, 201410% ownerSale7,105$23.48$166.8KForm 4
Jan 3, 2023Eckelman Living Trust Dated February 5, 201410% ownerSale32,895$23.76$781.7KForm 4
Dec 21, 2022Kayyem Jon FaizDirectorSale9,500$27.02$256.7KForm 4
Dec 19, 2022Lappe MarkChief Executive OfficerSale26,000$25.55$664.4KForm 4
Dec 6, 2022Eckelman Brendan P.Chief Scientific OfficerSale40,000$27.21$1.1MForm 4
Nov 21, 2022Kayyem Jon FaizDirectorSale9,500$29.89$284.0KForm 4
Nov 17, 2022Lappe MarkChief Executive OfficerSale26,000$27.88$724.9KForm 4
Nov 1, 2022Eckelman Brendan P.Chief Scientific OfficerSale40,000$33.51$1.3MForm 4
Oct 21, 2022Kayyem Jon FaizDirectorSale9,500$30.13$286.3KForm 4
Oct 17, 2022Lappe MarkChief Executive OfficerSale26,000$29.59$769.4KForm 4
Oct 7, 2022Ott David C.10% ownerBuy1,333,333$30.00$40.0MForm 4

All 26 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Aug 31, 2023Raised $200 million in a private offering of equity Form D: 5 investors so far Form D

SEC filer profile

How Inhibrx, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARInhibrx, Inc.1
  • CIK0001739614
  • Employer ID (EIN)82-42573121
  • Filer statusLarge accelerated filer1
  • Incorporated inCalifornia1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address11025 N. Torrey Pines Road, Suite 200, La Jolla, CA 920371
  • Phone(858) 795-42201
  • Shares outstanding52,401,941 as of Apr 30, 202411
  • Public float$892.9M as of Jun 30, 20235
  • On EDGAR sinceMay 10, 20181
  • Filings261 in all: 4 (70), 8-K (55), SC 13G/A (24), 144 (15), 3 (12), 10-Q (11), SC 13G (11), DEFA14A (9)1
    All 33 form types

    CORRESP (7), D (5), UPLOAD (5), 10-K (4), S-8 (4), S-8 POS (4), DEF 14A (3), DRS (2), S-1 (2), S-1/A (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), CERT (1), DEFM14A (1), DRS/A (1), DRSLTR (1), EFFECT (1), POSASR (1), PREM14A (1), RW (1), S-1MEF (1), S-3ASR (1)

  • Latest filingsAnnual report (10-K) Feb 28, 2024
    Quarterly report (10-Q) May 9, 2024
    Proxy statement (DEF 14A) Apr 13, 2023
    Latest 8-K (8-K) May 30, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
    SEC EDGAROther events
  23. 23
  24. 24
    SEC EDGAROther events
  25. 25
    SEC EDGAROther events
  26. 26
  27. 27
  28. 28
  29. 29
    SEC EDGAROther events
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44